Tildrakizumab

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.

Tildrakizumab exhibited real-world efficacy and safety for long-term treatment of plaque psoriasis, according to a study.

Tildrakizumab was efficacious in the treatment of patients with moderate to severe plaque psoriasis affecting the scalp and presented no new safety signals, according to a study.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor tildrakizumab from the Maui Derm 2024 meeting.

Dermatologists should consider prescribing topical halcinonide 0.1% ointment as an adjunctive therapy for patients with moderate to severe plaque psoriasis that inadequately respond to biologics, according to a study.

After 28 weeks of treatment, tildrakizumab significantly improved clinical status and reduced disease activity while also maintaining a consistent safety profile among patients with moderate to severe plaque psoriasis, according to a study.

Ilumetri significantly improved well-being in patients with moderate to severe plaque psoriasis after 16 weeks, Almirall announced in a press release.

BOSTON — Patients with moderate to severe plaque psoriasis experienced significant improvement after treatment with tildrakizumab in a real-world study, according to a poster presented at the American Academy of Dermatology Annual Meeting.

In this video from AAD VMX 2021, Stephen Rozzo, PhD, senior director of dermatology medical affairs at Sun Pharmaceuticals, discusses meeting presentations showing lasting efficacy of tildrakizumab for the treatment of plaque psoriasis.

Tildrakizumab continued to demonstrate efficacy after 5 years of treatment for psoriasis, according to pooled data from the reSURFACE 1 and reSURFACE 2 trials.